Gero.AI, a biotech company rewriting human aging with physics and AI, has engaged an Advisor to support the company’s strategic growth and platform evolution.
The Advisor will provide guidance on how best to position and apply Gero.AI’s target identification and project initiation capabilities within the broader biopharma landscape. This includes helping the company align its scientific approach, development strategy, and external partnerships as it expands its pipeline.
This appointment strengthens Gero.AI’s ability to translate its technical platform into impactful, industry-ready drug discovery programs.





